Loading
Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.
Previous close
$5.33
+$0.92 · +20.86%
Regular session · ET · Market data may be delayed.
Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.
Day range
Current $5.33
52-week range
Current $5.33
Regular session · ET · Market data may be delayed.
Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.
Day range
Current $5.33
52-week range
Current $5.33
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 4.94M USD | 4.39M USD | 5.04M USD | 4.11M USD |
| Cost of goods sold | 4.74M USD | 4.5M USD | 7.35M USD | 9.1M USD |
| Gross profit | 200K USD | −112K USD | −2.31M USD | −4.99M USD |
| Research and development | 3M USD | 3.38M USD | 2.21M USD | 1.9M USD |
| Selling, general, and administrative | 10M USD | 10.22M USD | 10.98M USD | 4.18M USD |
| Operating expenses | 13M USD | 13.6M USD | 13.19M USD | 6.08M USD |
| Interest income | — | — | 2K USD | 9K USD |
| Interest expense | — | 3.07M USD | 140K USD | 5K USD |
| Depreciation and amortization | 512K USD | 543K USD | 585K USD | 545K USD |
| Operating income | −12.8M USD | −13.71M USD | −15.5M USD | −11.07M USD |
| Net income | −27M USD | −21.06M USD | −15.57M USD | −11.17M USD |
Company facts updated Sep 12, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 3, 2026 | 1:50 | — | — |
Effective Aug 3, 2026
1:50
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
